JUL 21, 2016 2:28 PM PDT

Liquid Biopsy Predicts Ovarian Cancer Relapse

WRITTEN BY: Xuan Pham

Ovarian cancers have one of the highest mortality rates, ranking fifth in cancer deaths among women. Of the 22,000 new estimated cases of ovarian cancer this year, only 10-15 percent of patients will be successfully treated. Unfortunately, in the large percent of remaining patients, the cancer doesn’t respond to treatment, or will inevitably return with a vengeance.

Now researchers at the Mayo Clinic say a new non-invasive test could predict whether the cancer is likely to return years before it compromises the survival of the patients. This diagnostic test could transform how doctors monitor and preemptively treat ovarian cancer to increase patient outcome.

Image credit: Pixabay.comThe diagnostic test for ovarian cancer relapse relies on measuring the amount of tumor DNA in the blood – a process known as a liquid biopsy. Circulating tumor DNA (ctDNA), also known as cell-free tumor DNA, is genetic material from the tumor that’s freely floating in the bloodstream of cancer patients. ctDNA represents a non-invasive cancer biomarker that can indicate the presence of disease.

In this case, the research team asked whether ctDNA can predict the recurrence of a disease. They sampled blood from 10 patients with ovarian cancer before and after surgery. They also collected DNA from the actual tumor that was removed during surgery. Using mate-pair sequencing, the team showed that patients whose post-surgery blood have DNA matching that of the tumor were more likely to have cancer relapse. By contrast, patients whose post-surgery blood DNA didn’t align with the tumor DNA were more likely to be in remission.


"With liquid biopsies, we don't have to wait for tumor growth to get a DNA sample," said George Vasmatzis, researcher at the Mayo Clinic Center for Individualized Medicine, and senior author of the study. "This important discovery makes it possible for us detect recurrence of the disease earlier than other diagnostic methods. We can repeat liquid biopsies to monitor the progression of the cancer. That gives hope of a better treatment plan over time."

Advantages of this test could be multifold. First, sequencing the tumor identifies specific mutations that could define which treatment option would be best for patients. Second, that the test can predict cancer recurrence will allow doctors to monitor and treat the cancer preemptively, leading to more positive survival outcomes. And considering that the median survival for recurrent ovarian cancer is only 1-2 years, every effort counts.

Additional source: Mayo Clinic press release
 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JAN 08, 2020
Health & Medicine
JAN 08, 2020
Major Study Does Not Find Strong Link Between Talcum Powder and Cancer
Competing opinions regarding the safety of talcum powder have developed throughout the past several decades. Talc is commonly used as baby powder and is al...
JAN 13, 2020
Cancer
JAN 13, 2020
The anti-cancer properties of bitter melon
New research published in the journal Cell Communication and Signaling suggests that bitter melon, also known as bitter gourd, may have anti-cancer propert...
JAN 15, 2020
Drug Discovery & Development
JAN 15, 2020
Acid-Reflux Drugs May Negatively Impact Breast Cancer Survivors
Many of us have taken some form of an acid-reflux drug—especially after a meal that causes discomfort. However, now researchers are indicating that s...
JAN 21, 2020
Cannabis Sciences
JAN 21, 2020
Medical Marijuana Ineffective for Long Term Pain Management
Medicinal cannabis may not as effective as once thought as a solution for sleep problems for those with chronic pain in the long run, according to new find...
FEB 10, 2020
Cancer
FEB 10, 2020
New hope for KRAS-mutant pancreatic cancers
A study published recently in the journal Cancer Research showcases the findings from new research on pancreatic cancer. The study was led by Frank Mc...
FEB 16, 2020
Cell & Molecular Biology
FEB 16, 2020
Growing Cells on Scaffolding as an Alternative to Animal Models
Researchers may have just made it easier for investigators to switch to an engineered model and replace their animal colonies with electrospun synthetics....
Loading Comments...